Key Highlights

  • Barclays downgraded Cellectis S.A. from Overweight to Underweight on September 16, 2026.
  • The firm significantly reduced its price target from $9.00 to $1.30.
  • The downgrade represents a sharp Reversal in Barclays' prior view on the stock.

Barclays downgraded Cellectis S.A. (NASDAQ: CLLS) from Overweight to Underweight on September 16, 2026, significantly reducing its price target from $9.00 to $1.30.

Company Overview

Cellectis is a clinical-stage biopharmaceutical company specializing in gene-editing technology, particularly its proprietary TALEN gene-editing platform, which it has applied to developing allogeneic CAR T-cell immunotherapies and other gene-edited product candidates for cancer and other serious diseases. The company has historically positioned its allogeneic, or off-the-shelf, approach to CAR T-cell therapy as a potential advantage over autologous therapies that require using a patient's own cells.

The company recently announced a strategic pivot toward in vivo gene-editing programs, concentrating resources on HEAL-101 for APOC3 in severe hypertriglyceridemia and HEAL-201 for PCSK9 in severe hypercholesterolemia, while discontinuing clinical work on its lasme-cel and eti-cel CAR T-cell candidates to extend its operational cash runway into the second half of 2028.

What Happened

The scale of the price target cut, from $9.00 to $1.30, represents one of the more dramatic single-day analyst reversals for the stock, reflecting a significant reassessment of the company's near-term prospects by the firm.

Market Reaction

The disclosed information does not include stock price or trading data for Cellectis following the downgrade, though a rating change and price target cut of this magnitude from a major bank would typically be expected to weigh on sentiment.

Outlook

Cellectis's recently announced pivot toward in vivo gene-editing programs, HEAL-101 and HEAL-201, with initial Phase 1 readouts expected in the second half of 2027 and first half of 2028, represents the company's new primary focus following the discontinuation of its CAR T-cell programs.